MedTrace Logo

A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis

NCT01284647 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2014-01-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of teprenone on chronic non-atrophic erosive gastritis and its therapeutic mechanism

Conditions

  • Chronic Erosive Gastritis

Interventions

DRUG

Teprenone capsule and placebo of sucralfate

Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.

DRUG

Sucralfate and placebo of teprenone

Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks

Sponsors & Collaborators

  • Eisai China Inc.

    collaborator INDUSTRY

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhaoshen Li · Changhai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-10-31
Completion
2013-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284647 on ClinicalTrials.gov